Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study

INTRODUCTION: Treatment resistance schizophrenia (TRS) develops in ~ 30% of patients in about 5 years from starting treatment with 5-HT2/D2 APs, resulting in increased morbidity, suicidality, and mortality. Findings from neurochemistry, neurometabolism, functional imaging in TRS patients indicate ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, R., Hartman, R., Lucini, V., Giuliani, R., Turolla, A., Chinellato, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661346/
http://dx.doi.org/10.1192/j.eurpsy.2023.1329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661346/
http://dx.doi.org/10.1192/j.eurpsy.2023.1329

Ejemplares similares